217 results about "Tetanus" patented technology

A hybrid protein contains a protein that binds to a receptor of mastocytes and basophils and is endocyted by them. The protein can be IgE; IgE fragment; IgE Fc fragment; antibody against IgE receptor of mastocytes and basophils; fragment of the antibody against the IgE receptor of mastocytes and basophils; antibody against mastocyte specific potassium channel; and mast cell degranulating peptide. The hybrid protein also contains a protease cleaving proteins of the secretion process of the mastocytes and basophils so as to inhibit the secretion process without killing the mastocytes and basophils. The protease can be light chain Clostridium botulinum toxin; proteolytically active fragment of the light chain of a Clostridium botulinum toxin containing an amino acid sequence His-Xaa-Xaa-Xaa-His-Xaa-Xaa-His wherein Xaa is an amino acid; light chain of the tetanus toxin; proteolytically active fragment of the light chain of the tetanus toxin containing His-Asp-Leu-lIe-His-Val-Leu-His; IgA protease of Neisseria gonorrhoeae; and proteolytic domain of the IgA protease of Neisseria gonorrhoeae.

The invention relates to a method for producing health care black bone chicken egg and employed pharmaceutical composition. The production method of the health care black bone chicken egg comprises the following steps: (1) respectively grinding and then evenly mixing medicinal materials in the main drug; (2) respectively grinding and then evenly mixing medicinal materials in the adjuvant; (3) fully mixing the main drug and the adjuvant obtain in step (1) and step (2) to obtain the pharmaceutical composition, wherein the proportioning is weight of main drug: weight of adjuvant=80-150:100; (4) adding the pharmaceutical composition to the feed to be evenly mixed to form a mixed feed; wherein the additive amount is that weight of the pharmaceutical composition: weight of the feed=5-20:100; (5) feeding the mixed feed obtained in step (4) to egg-producing black bone chicken, then obtaining the health care black bone chicken egg which is produced after feeding the black bone chicken for 7 days.The pharmaceutical composition is rationally matched by selecting multiple medicines, through efficient biotransformation of the egg-producing black bone chicken, cream of Chinese herbal medicines are concentrated in the eggs, so that the health care black bone chicken eggs with multiple health care and treatment functions are obtained; the health care black bone chicken eggs enjoy excellent food therapy effect in preventing and treating diabetes, high blood pressure, hemiplegia, sequel of apoplexy, cardiovascular and cerebrovascular diseases, rheumatism and paralysis, tetanus, infertility and various cancers.

The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided

The invention provides a diphtheria, tetanus and acellular pertussis / Haemophilus influenzae type b - group A and C meningococcus combined vaccine, which has the characteristics of high safety, high efficacy, high controllability and prevention of multiple diseases through one injection, satisfies relevant requirements on absorbed diphtheria, tetanus and acellular pertussis combined vaccines, Haemophilus influenzae type b combined vaccines and group A and C meningococcus combined vaccines in the Third Part of Chinese Pharmacopoeia (2010) and proposed Rules on Production and Inspection of Diphtheria, Tetanus and acellular Pertussis / Haemophilus influenzae Type b - Group A and C Meningococcus Combined Vaccines, and achieves an effect of putting into practical application.

Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 μg / ml; and (c) the Hib conjugate has never been lyophilised.

The invention discloses a clostridial neurotoxin substrate protein, and a coding gene and an application thereof. The clostridial neurotoxin substrate protein is a protein (a) composed of an amino acid sequence represented by sequence 2 in a sequence table, or is a protein (b) obtained through substituting and / or deleting and / or adding one or more amino acid residues to the amino acid sequence represented by the sequence 2, related to the clostridial neurotoxin detection and derived from the sequence 2. The substrate protein SNVP provided by the invention has seven toxin serotype botulinum and tetanus toxin enzyme hydrolysis sites, can specifically identify A, B, E, C, D, F and G type botulinum toxins and tetanus toxins, and can be used for the detection and the parting discrimination of the botulinum toxins and tetanus toxins as a core detection reagent.

Disclosed are vaccines and vaccine adjuvants useful in the treatment and / or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating / immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvants are demonstrated to enhance the immunogenicity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.

Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.

The invention discloses a medical hemostasis first-aid belt and a hemostyptic thereof. The first-aid belt comprises a body, wherein the periphery of the bottom surface of the body is provided with a gluing region at which an oily leather is arranged; the middle part of the body is provided with a hemostasis bag; and vacuum air bags are arranged at the periphery of the hemostasis bag. In addition, the invention further discloses the hemostyptic used for the medical hemostasis first-aid belt. The hemostyptic comprises medicaments with hemostasis, diminish inflammation, analgesia, infection prevent and tetanus prevention effects, such as common cephalanoplos herb, pseudo-ginseng, cicada slough, rhizoma arisaematis, corydalis tuber, bezoar, borneol, pearl powder, red paeonia, excrementum pteropi and dalbergia wood. Since the technical scheme is adopted, compared with the prior art, the medical hemostasis first-aid belt disclosed by the invention has the characteristics of simple structure, convenience in use, portability, good hemostasis effect, less possibility of infection, wide application range and the like.

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal Tcell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.

The invention relates to human rotavirus Delta VP8* subunit recombinant protein and application thereof. The human rotavirus Delta VP8* subunit recombinant protein comprises a T cell epitope P2 in tetanus toxin and a rotavirus Delta VP8* subunit. By the recombinant protein disclosed by the invention, the immune efficacy of a Delta VP8* subunit vaccine can be greatly improved; faster and stronger neutralization antibody titer can be induced; moreover, anti-p[4] genotype specific rotavirus cross neutralization antibody of high titer can be induced; simultaneously, the potential risk of inducing intussusception by taking attenuated rotavirus vaccine orally can be overcome; therefore, the recombinant protein is applicable to preparing a rotavirus vaccine.

The invention discloses application of vaccarin in treating open skin lesions, and belongs to the technical field of application of a traditional Chinese medicine. The invention discovers firstly the activity of the vaccarin in promoting healing of open skin lesions, and the vaccarin is applicable to a series of diseases including diabetic foot, ulcer, tetanus, infection, rash, pathological scars, body's malnutrition, tissue necrosis, metabolism imbalance and the like related to the open skin lesions. The vaccarin is applicable to pharmaceutical preparations, cosmetics and the like.